{"id":"W4415918848","doi":"10.1038/s41467-025-64130-6","title":"Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Health and Medical Research Council; Genentech; Sierra Oncology; Cancer Council Victoria; Eisai; BeiGene; Clovis Oncology; University of Sydney; Australian Cancer Research Foundation; Pfizer; Australian Government; Gilead Sciences; RMIT University; Genomic Health; AstraZeneca; Eli Lilly and Company","keywords":"Olaparib; Clinical endpoint; Ovarian cancer; Homologous recombination; Priming (agriculture); PARP inhibitor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001196468,0.001095545,0.001392442,0.0002572798,0.00016966,0.000800007,0.0005166154,0.0007528518,0.003038003],"category_scores_gemma":[0.0009468416,0.0003157634,0.0009848595,0.0003737436,0.0004721894,0.0005195047,0.0003670038,0.001758756,0.0003443397],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000747532,"about_ca_system_score_gemma":0.000759453,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006643384,"about_ca_topic_score_gemma":0.002120998,"domain_scores_codex":[0.9996796,0.0001774366,0.00001341546,0.00005134036,0.00003483035,0.00004339091],"domain_scores_gemma":[0.9995485,0.00009760865,0.0001130205,0.00004237741,0.00002282924,0.0001755767],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9256016,0.005266412,0.005476641,0.0005821353,0.001260946,0.00007062277,0.00005599694,0.001237996,0.008179283,0.0002644903,0.00300252,0.04900127],"study_design_scores_gemma":[0.9223195,0.06048826,0.009455779,0.00004746624,0.0007329108,0.0001720568,0.00003224614,0.001101588,0.002287994,0.000364157,0.002975684,0.00002239319],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905494,0.004781799,0.0002392195,0.000600032,0.0001584057,0.0007227801,0.001377951,0.00005492727,0.00151562],"genre_scores_gemma":[0.9867992,0.002721991,0.001081333,0.0009787709,0.0002064207,0.001525567,0.003627139,0.00002161805,0.003037989],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003038003,"threshold_uncertainty_score":0.01016307,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01629599025378721,"score_gpt":0.3527248419449789,"score_spread":0.3364288516911917,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}